Furthermore, in a Japanese study conducted in a pediatric AML cohort, NRAS mutations were associated with a good outcome, while the impact of KRAS mutations could not be assessed due to the small number of patients [79]. This evidence concerns the gene NRAS and acute myeloid leukemia.